Chongqing Haisco Pharmaceutical Group Deal History & Licensing Activity
Chongqing Haisco Pharmaceutical Group is a biotech headquartered in China. Over the past three years, Chongqing Haisco Pharmaceutical Group has been involved in 4 licensing and acquisition transactions, with a primary focus on Other (4 deals). The company currently has 48 active clinical trials, primarily in Respiratory.
Deals (12mo)
4
Active Trials
48
Top Modality
Other
Focus Area
Respiratory
Chongqing Haisco Pharmaceutical Group Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Chongqing Haisco Pharmaceutical Group in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| Preclinical type 2 inflammatory-disease asset | Sentivera | Other | Preclinical | license | Aug 25, 2026 |
| NXP100 and NXP200 | Nuvectis Pharma | Small Molecules | Phase 2 | license | Jun 22, 2026 |
| Haisco collaboration program | Eli Lilly | Other | Unknown | collaboration | Jun 1, 2026 |
| HSK55718 and HSK51155 | AbbVie | Small Molecules | Preclinical | license | Apr 14, 2026 |
Chongqing Haisco Pharmaceutical Group Pipeline Focus
Therapeutic areas and modalities where Chongqing Haisco Pharmaceutical Group is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Chongqing Haisco Pharmaceutical Group Clinical Pipeline
Chongqing Haisco Pharmaceutical Group has 48 active clinical trials across 6 development phases.
1
Not Applicable
1
Phase 4
15
Phase 1
2
Phase 1/2
18
Phase 2
11
Phase 3
See How Your Asset Matches Chongqing Haisco Pharmaceutical Group's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Respiratory assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Chongqing Haisco Pharmaceutical Group Licensing & Deal Activity
Chongqing Haisco Pharmaceutical Group is a biotech company based in China that has been actively engaged in licensing transactions across the biopharma landscape. With 4 deals over the past three years, Chongqing Haisco Pharmaceutical Group ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Chongqing Haisco Pharmaceutical Group include Respiratory (11 deals and trials), Solid Tumors (7 deals and trials), Autoimmune (7 deals and trials), and Immunology (4 deals and trials). In terms of modality, Chongqing Haisco Pharmaceutical Group has shown particular interest in other, small molecules, small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Chongqing Haisco Pharmaceutical Group and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Chongqing Haisco Pharmaceutical Group's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.